What is adult non-Hodgkin lymphoma? NHL is a group of lymphocyte cancers with different cell types and growth patterns. NHS disease context. Biopsy identifies the actual disease; subtype, extent, symptoms and health guide specialist decisions.
Confidence: moderate to high for the selected diagnostic and safety distinctions. Care descriptions remain attributed clinical context; this review does not establish independently cleared superiority of an individual drug or supplement.
- The complete pathology name matters more than the umbrella “NHL” label.
- Stage, growth rate and molecular findings answer different questions.
- Watch and wait requires a selected diagnosis and planned specialist follow-up.
- A broad overview does not complete distinct rare subtypes or childhood care.
Table of contents
- Evidence summary
- What adult non-Hodgkin lymphoma means: B, T and NK cells
- The pathology report: cell appearance, markers and genetic findings
- Symptoms: painless lumps, sweats and disease outside a node
- Diagnosis: an adequate biopsy and specialist tissue interpretation
- Stage, grade and PET: different kinds of information
- Watch and wait: selected indolent disease needs active follow-up
- Treatment families: the subtype and treatment purpose come first
- Safety during care: infection, hepatitis B and immune side effects
- Fertility and follow-up: record the treatment actually received
- Nutrition, supplements and the limits of this evidence review
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis and extent | NHS tests; Aggressive B-cell PDQ | Public/gift routes; connected reviewer records traced separately. | Selected tissue and staging context; no personal testing schedule. |
| Classification | WHO; ICC | Declared support and separate author interests; historical CAC finance verified separately. | Naming context only. Genetic interpretation is not a prescription. |
| Observation and treatment | NHS care; Indolent B-cell PDQ | Clinical syntheses do not financially clear every supporting trial. | Selected subtype-specific care; no independently cleared regimen ranking. |
| Safety and support | NCI infection; NCI follow-up | Public accountability with source-specific contributor/trial gaps. | Urgent assessment and individual care plans; no self-directed drug changes. |
What adult non-Hodgkin lymphoma means: B, T and NK cells
Non-Hodgkin lymphoma, or NHL, is a group of lymphocyte cancers, distinct from Hodgkin lymphoma. NHS explains that lymphocytes are infection-fighting white blood cells moving through lymph vessels and nodes. NHS definition. The group name alone does not identify the disease to treat.
NCI describes B-cell, T-cell and natural killer, or NK-cell, disease and lymphoma outside lymph nodes. NCI cell-family context. “Extranodal” describes a location outside a node, not a separate universal treatment. A gut or skin presentation needs its own tissue interpretation.
This adult overview explains the shared diagnostic and care decisions. It does not complete individual follicular, diffuse large B-cell, mantle-cell, marginal-zone, Burkitt, T/NK, skin or immune-deficiency-related entities. Childhood pathways are also separate. A mention here is not a dedicated subtype guide, and a shared information-page destination does not make different diagnoses synonyms.
The pathology report: cell appearance, markers and genetic findings
WHO classification distinguishes disease families, entities and subtypes, incorporating molecular criteria. WHO framework. Obtain the full pathology report.
With MYC/BCL6 but no BCL2 rearrangement, WHO classifies cases by morphology as DLBCL, NOS or HGBL, NOS; ICC retains a provisional MYC/BCL6 entity. WHO naming; ICC naming. Increased gene copies do not substitute for rearrangements in these high-grade categories. ICC genetic distinction.
NOS means “not otherwise specified.” That label is part of the full pathology interpretation, not a reason to make a diagnosis from one abbreviation.
Ask which classification system the report uses and which tests remain pending. A gene result needs the tissue and clinical context; it does not independently supply a prescription. The newer naming difference is not itself proof of disease progression. A specialist explanation can establish whether reports from different hospitals describe the same case in different terminology.
Symptoms: painless lumps, sweats and disease outside a node
Possible symptoms include a painless neck, armpit or groin lump, fever or shivering, night sweats, itching, breathlessness and unexplained weight loss. NHS symptom recognition. Common conditions can produce similar symptoms; an urgent cancer referral is not proof of cancer.
Arrange assessment of an unexplained lump or concerning changes and follow referral instructions. Keep a brief record of when symptoms appeared, their locations and whether they are changing. Avoid repeatedly pressing a gland or using photographs to decide whether specialist investigation is necessary.
NHL may involve organs such as the gut and marrow as well as nodes. NCI location context. Therefore, the absence of a palpable lump does not supply a complete assessment. Bring previous scans, blood results and biopsy reports so the service can connect findings rather than treating each symptom in isolation.
Diagnosis: an adequate biopsy and specialist tissue interpretation
NHS identifies a lymph-node biopsy as the main diagnostic investigation, with blood tests, imaging or marrow examination considered afterward. NHS tests. Those procedures answer different questions; a list of possible tests does not mean everyone needs them all.
The aggressive B-cell NCI summary emphasizes experienced hematopathology review and planning tissue preparation before biopsy because special studies may be needed. NCI specimen context. Ask the service whether the specimen is adequate to distinguish the suspected diseases and whether specialist review is required.
The sampling method is chosen for the actual site and clinical question. This guide does not make every needle specimen sufficient or every person’s procedure an excision. Follow the service’s own preparation, anesthesia and medicine instructions; it gives no home fasting schedule or anticoagulant interruption. Obtain a named contact for pending pathology rather than interpreting an incomplete report yourself.
Stage, grade and PET: different kinds of information
Stage describes extent; growth rate and exact type also inform care. NHS stage and type. A low-grade label is not the same as early stage, and a fast-growing label is not a statement about how many organs are involved.
NCI’s aggressive B-cell summary describes Lugano staging and notes that its A/B designation is no longer used for NHL. Marrow biopsy is considered when it would change management or evaluate low blood counts. NCI staging and marrow roles. These are selected clinical distinctions, not a universal test timetable.
Clarify whether a scan is establishing extent, checking treatment response or investigating a new symptom. Do not infer a particular treatment from a stage number or a bright PET area alone. Likewise, this review does not treat advanced extent as automatically incurable; the treatment purpose must be explained for the actual subtype and clinical situation.
Watch and wait: selected indolent disease needs active follow-up
NHS describes supervised observation with regular tests for selected slow-growing NHL; fast-growing disease needs prompt treatment. NHS growth-rate care distinction. Observation is a planned clinical pathway, not permission to miss appointments or delay initial assessment.
For selected asymptomatic follicular disease, NCI describes watchful waiting; FLIPI/FLIPI-2 scores do not establish a need for treatment. NCI observation and score limits.
Keep the written monitoring plan, the responsible service and the changes it wants reported. New or worsening symptoms should trigger contact rather than waiting for a pre-existing scan date. The decision to begin treatment combines the actual disease and current clinical findings; this article gives no node-size threshold, blood-count trigger or personal observation interval.
Treatment families: the subtype and treatment purpose come first
Current NHS care includes selected combinations of chemotherapy, targeted medicines, immunotherapy and radiotherapy; stem-cell transplantation may be considered in particular relapsed or nonresponding cases. NHS care families. The selection depends on type, location, symptoms, extent and overall health.
Ask whether the plan aims to eradicate the lymphoma, control it over time, relieve a complication or bridge to another treatment. A first diagnosis, recurrence and a different pathology finding need their own specialist explanation. Ask what evidence establishes the present problem before applying a treatment description from an earlier report.
These are attributed care descriptions, not independently cleared comparisons between branded products or regimens. A meaningful comparison needs disease control, quality of life, symptoms and harms, not only laboratory response. Obtain the actual medicine names and written infusion, missed-dose and vomiting instructions. Dose, duration and whether to change a treatment remain prescribing decisions.
Safety during care: infection, hepatitis B and immune side effects
Possible infection during cancer treatment needs prompt oncology contact; fever-reducing medicines may hide a warning. NCI infection precautions. Keep an after-hours number and the team’s urgent assessment instructions. Do not wait for the next infusion when becoming acutely unwell.
NCI identifies hepatitis B reactivation risk after a previous infection in relevant treatment contexts. NCI hepatitis B context.
Tell the service about prior hepatitis results and ask what testing, monitoring or prevention applies to the planned medicines. This guide supplies no antiviral, vaccine or monitoring regimen.
Immunotherapy can inflame healthy tissues during or after treatment. NCI adverse-effect context. Report new breathing problems, diarrhea or other changes to the responsible service. Severe breathing difficulty, collapse, uncontrolled bleeding, severe allergic symptoms or a new seizure needs emergency help. Bring the treatment list; do not self-prescribe steroids or antibiotics from an online protocol.
Fertility and follow-up: record the treatment actually received
Discuss future fertility before treatment. NCI’s female fertility and male fertility resources explain that effects depend on the treatment and personal circumstances. Request specialist input early if future parenting matters.
No preservation method, later pregnancy or drug exposure is declared safe or effective here. If pregnancy is possible or confirmed, promptly involve the lymphoma and maternity teams. This overview does not transfer an older PDQ’s pregnancy-drug reassurance into an individual care decision.
NCI supports a written treatment summary and follow-up plan. NCI follow-up planning. Keep the actual medicines, radiation sites and significant adverse effects available to clinicians. The plan should identify who follows the lymphoma, who handles ongoing symptoms and how the services share results. A relative’s scan schedule or another survivor’s treatment does not establish your follow-up needs.
Nutrition, supplements and the limits of this evidence review
NCI distinguishes nutrition support from unproven diets or supplements claimed to treat cancer. NCI nutrition boundary. Restrictive diets and “immune-boosting” products do not thereby establish NHL control. Report difficulties maintaining intake so support addresses the actual problem.
Interactions depend on the anticancer medicine and the product ingredients. NCI interaction context. Give the oncology pharmacist complete labels, including intermittent products and nonprescription medicines. Do not replace lymphoma care with a supplement or use a generic “natural” label as interaction clearance.
This review separates classification, clinical summaries and financial declarations. Cell-line results, animal studies and mechanism diagrams cannot establish human survival or quality-of-life benefit. Manufacturer efficacy is excluded from the independent verdict; underlying trials and complete contributor receipts remain unresolved. The adult umbrella leaves rare diagnoses and childhood pathways explicitly incomplete rather than claiming them covered by a passing mention.
Funding and source roles
Research funding at a glance
30 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: adult NHL patient PDQ | NCI institutional routes below; separately dated reviewer records do not establish page payments. Supporting-study finance remains unclosed. | United States; NCI, Bethesda, Maryland. | Tier 3 connected reviewer chain, provisional; clinical context only. | C, provisional — 22 August 2024; patient derivation stated, exact historical reviewer chain unclosed. Expert synthesis, not a formal guideline. |
| NCI: indolent B-cell professional PDQ | NCI institutional routes below; separately dated reviewer records do not establish page payments. Supporting-study finance remains unclosed. | United States; NCI, Bethesda, Maryland. | Tier 3 connected reviewer chain, provisional; clinical context only. | C, provisional — 14 May 2025; indolent B-cell scope only. Expert synthesis, not a formal guideline. |
| NCI: aggressive B-cell professional PDQ | NCI institutional routes below; separately dated reviewer records do not establish page payments. Supporting-study finance remains unclosed. | United States; NCI, Bethesda, Maryland. | Tier 3 connected reviewer chain, provisional; clinical context only. | C, provisional — 12 May 2025; aggressive B-cell scope only. Expert synthesis, not a formal guideline. |
| NHS: what NHL is | National website policy documents DHSC funds and no corporate sponsorship or advertising. Page receipts unknown. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL symptoms | National website policy documents DHSC funds and no corporate sponsorship or advertising. Page receipts unknown. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL tests | National website policy documents DHSC funds and no corporate sponsorship or advertising. Page receipts unknown. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL treatment | National website policy documents DHSC funds and no corporate sponsorship or advertising. Page receipts unknown. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NCI: infection during cancer treatment | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 23 January 2020; dated safety context. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: immunotherapy side effects | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 16 February 2023. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: female fertility | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: male fertility | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: follow-up medical care | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 2 December 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: nutrition and cancer claims | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Posted 30 October 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: food and supplement interactions | Congressional funds; separate public gift route. Exact page and study allocations unknown. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 25 April 2024. Page and contributor receipts, and underlying-study finances, are unclosed. PDQ is an information summary, not a treatment guideline. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
| Greenspring Personal Oncology: Seifter service identity | Own page identifies Seifter as oncology lead and lists commercial insurers, Medicare and patient billing. Actual receipts and PDQ payments unknown. | United States; 2328 West Joppa Road, Lutherville, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own page. No audited income, manufacturer-payment or disease-page sponsor inferred. |
| WHO lymphoid classification, 2022 | Original: Projekt DEAL open-access support; no competing interests declared. Separate 2025 coauthor interests do not establish 2022 payments. | International authors; corresponding authors United Kingdom, United States and Germany. | Tier 3 known separately connected coauthor; taxonomy only. | C, provisional — 22 June 2022. Expert taxonomy; complete receipts unclosed. Authorship correction below. |
| WHO classification authorship correction, 2023 | Original correction declares no competing interests; no separate production-money statement found. It corrects authors and affiliations. | International authors; corrected affiliations include Italy and Japan. | Tier 3 financially connected author group; record correction only. | C, provisional — 19 July 2023 full correction read. No treatment or classification outcome inferred from its authorship amendment. |
| Campo et al.: International Consensus Classification, 2022 | NCI/NIAID intramural support; CAC funding refers to 2016 financial record. Authors declare no competing financial interests; allocations unclosed. | International authors; corresponding contacts Barcelona, Spain, and Bethesda, United States. | Tier 3 financially connected funding chain; taxonomy only. | C, provisional — 15 September 2022 issue, online 2 June. Full 25-page original selected sections read; old project chain and supporting studies not cleared. |
| Swerdlow et al.: cited 2016 financial chain | Primary acknowledgments verify charitable/university and drug/test-company support for the Chicago CAC meeting, 31 March–1 April 2014, including Genentech, Incyte and Celgene. | International authors; historical meeting Chicago, United States. | Tier 4 manufacturer-supported historical project; finance only. | D for efficacy; C for historical financial trace — 19 May 2016. Complete primary author copy’s financial footer verified; direct publisher access failed. No inference of identical 2022 sponsors or receipts. |
| ICC erratum record, 2023 | PubMed record identifies the original ICC authors and January 2023 Figure 4 correction; no separate production-funding statement present. | United States; NLM index, Bethesda; original authors international. | Tier 3 administrative record, provisional. | C, provisional — 26 January 2023. Actual record/figure legend read; complete publisher correction body unavailable. No amended image or grading claim adopted. |
| DEAL: publication-payment mechanism | Own description: institutional publication/read fees replace subscription payments; agreements with commercial publishers. Not funding of clinical research itself. | Germany; DEAL Open Access Services, Landsberger Strasse 346, Munich. | Tier 3 institutional financial self-report. | C, provisional — undated body. Publishing access/cost remit favors traceable information; exact 2022 article payer and ledger remain unclosed. |
| ELN 2025: separately dated Hochhaus interests | ELN meeting support, no commercial production funding declared. Hochhaus: Enliven/Incyte/Novartis honoraria and institutional company research, including BMS and Pfizer. | International authors; Hochhaus affiliation Jena, Germany. | Tier 3 connected authors; financial record only. | C, provisional — 11 July 2025 original declarations read. Later relationships are not proof of money for the 2022 classification. |
| Sterling et al.: dated financial declaration, 2024 | Publisher declaration: Sterling had Jerome Greene Foundation support and Medical Logix/Haymarket consulting. Coauthor Paul’s patents/company ties are not assigned to Sterling. | United States; author affiliation Johns Hopkins, Baltimore; publisher MDPI, Switzerland. | Tier 3 known paid education-company consultant; finance only. | C, provisional — 15 October 2024 indexed original declarations read. Direct publisher 429/PMC challenge prevented full read. No inference of PDQ payment or current contracts. |
| Johns Hopkins: Sterling provider profile | Own profile identifies lymphoma care and lists insurer networks, including Aetna and Cigna. Exact clinical, research and PDQ receipts remain unknown. | United States; listed cancer-center location 401 North Broadway Street, Baltimore, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own profile. No audited income or personal manufacturer payments inferred; patient ratings excluded. |
| Medical Logix: separate sponsored education project | Own 14 November 2025 course identifies Regeneron educational grant and Medical Logix/Partners joint provision. Not evidence this donor paid Sterling or funded PDQ. | United States educational activity; company headquarters not established by this page. | Tier 4 manufacturer-supported education; finance only. | D for independent efficacy; C for financial self-report — exact project/date checked. Grant size, full company accounts and NHL allocation remain unclosed. |
| Haymarket: educational platform services | Own page markets client activity hosting, promotion, reporting and paid board-review courses. Specific clients, contracts and Sterling receipts unclosed. | Operator serves medical-education clients; exact headquarters not verified in this source. | Tier 4 commercial service promotion; finance only. | D for independent efficacy; C for financial route — undated own body read. Client-service incentives disclosed; engagement claims and clinical outcomes not adopted. |
Frequently asked questions
Is non-Hodgkin lymphoma one disease? No. It is an umbrella for different lymphocyte cancers. Keep the full pathology name; subtype-specific guides and childhood pathways remain separate.
Can a blood test or scan replace the biopsy? They answer different questions. The team must establish the actual diagnosis and whether the tissue or other selected evidence is adequate; the investigation section explains the distinction.
Does low grade mean early stage? No. Growth rate and disease extent are different. Ask which information each term describes in the actual report.
Can all patients use watch and wait? No. Selected slow-growing disease may be observed under a specialist plan. That is not advice to defer treatment for aggressive disease or postpone assessment.
Does a late stage always mean the lymphoma cannot be cured? Stage alone does not establish the treatment purpose. Discuss the confirmed subtype, clinical situation and proposed aim with the lymphoma team; this overview gives no prognosis percentage.
Can supplements replace treatment or prevent relapse? This review establishes no independent supplement control or relapse-prevention benefit for NHL. Share products with oncology for medicine-specific review and follow the prescribed care plan.
Sources and funding notes
The patient PDQ states professional derivation. The former general professional URL now redirects to indolent B-cell care; the separate aggressive B-cell page is not a T/NK guideline. Seifter and Sterling are named leads on both current professional pages. Separate provider and dated consulting records do not establish payments for NCI pages. Sterling’s indexed original declaration has an explicit direct full-access gap. WHO/ICC classification and their corrections support selected naming only; old trial outcomes, historical subtype lists, specific drug-approval menus and blanket pregnancy reassurance are excluded.
- NCI: adult NHL patient PDQ — Selected cell-family and extranodal context; patient derivation.
- NCI: indolent B-cell professional PDQ — Selected follicular observation, risk-score and hepatitis B boundaries.
- NCI: aggressive B-cell professional PDQ — Selected specimen, staging and marrow roles; actual reviewer identity.
- NHS: what NHL is — Disease versus growth-rate context.
- NHS: NHL symptoms — Symptoms and referral distinction.
- NHS: NHL tests — Biopsy and possible further investigations.
- NHS: NHL treatment — Selected treatment families and supervised observation.
- NCI: infection during cancer treatment — Urgent infection precautions only.
- NCI: immunotherapy side effects — Healthy-tissue inflammation and reporting only.
- NCI: female fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: male fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: follow-up medical care — Written follow-up plan and treatment record.
- NCI: nutrition and cancer claims — Nutrition versus unproven anticancer diets.
- NCI: food and supplement interactions — Medicine-specific interaction review only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
- Greenspring Personal Oncology: Seifter service identity — Named reviewer’s private-provider relationship only.
- WHO lymphoid classification, 2022 — Selected family, morphology and genetic naming distinctions.
- WHO classification authorship correction, 2023 — Corrected author/institution record only.
- Campo et al.: International Consensus Classification, 2022 — Selected diagnostic and genetic naming distinction.
- Swerdlow et al.: cited 2016 financial chain — Historical funding trace only; no clinical findings.
- ICC erratum record, 2023 — Correction awareness; no figure-derived clinical claim.
- DEAL: publication-payment mechanism — Open-access payment route and operator identity only.
- ELN 2025: separately dated Hochhaus interests — WHO coauthor relationship only; no CML clinical claims.
- Sterling et al.: dated financial declaration, 2024 — Reviewer relationship only; no therapy findings.
- Johns Hopkins: Sterling provider profile — Named reviewer identity and provider relationship only.
- Medical Logix: separate sponsored education project — Consultant-company money route only; unrelated course.
- Haymarket: educational platform services — Consultant-company commercial-service route only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.